New Journey(SZ:002219) Quan Jing Wang·2025-12-23 10:47Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the updated drug directories, marking a significant step in improving the accessibility of innovative drugs and reducing patient burdens in China [1] - Two important new drugs targeting the PAM/PI3K signaling pathway for HR-positive/HER2-negative advanced breast cancer have been included in the updated directory: Roche's Inalyse tablets and AstraZeneca's Capivasertib tablets [1] - Inalyse is indicated for use in combination with Palbociclib and Fulvestrant for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have developed resistance to endocrine therapy [1] - Capivasertib is indicated for use in combination with Fulvestrant for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy [1] Group 2 - Geneplus, a leader in tumor precision testing, provides reliable and comprehensive testing solutions, ensuring coverage of key mutations in PIK3CA, AKT1, and PTEN for clinical decision-making [2] - The Geneplus Jizhi® intelligent analysis system enables efficient local closed-loop testing, ensuring rapid delivery of results within 24 hours to facilitate timely patient treatment [2] - Geneplus aims to advance breast cancer diagnosis and treatment towards a more standardized and individualized era, benefiting patients from national policies and technological advancements [2]